# Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)

> **NCT02827227** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 99 (actual)

## Conditions studied

- HIV-infected Patients

## Interventions

- **BIOLOGICAL:** lymphocytes immunophenotyping

## Key facts

- **NCT ID:** NCT02827227
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2016-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02827227

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02827227, "Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02827227. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*